Neuronetics Stock Drops 2.8% Amid Analyst Downgrades

Shares of the medical technology company fall as Wall Street sours on its outlook.

Apr. 16, 2026 at 4:08am

Got story updates? Submit your updates here. ›

A close-up, cinematic view of the intricate inner workings and machinery of a modern medical device, representing the complex technology behind Neuronetics' neuromodulation therapy. The image has a sense of precision and power, with muted tones of steel, copper, and glass.The specialized machinery and components that power Neuronetics' non-invasive brain stimulation technology face increased scrutiny from Wall Street as the company navigates a competitive mental health treatment market.Malvern Today

Neuronetics, Inc. (NASDAQ:STIM), a company that develops non-invasive neuromodulation therapies, saw its stock price drop 2.8% during mid-day trading on Wednesday. The decline came as Wall Street analysts downgraded the stock, with one firm cutting its price target from $7 to $3 and another moving the rating to 'sell'.

Why it matters

Neuronetics' flagship product, the NeuroStar Advanced Therapy System, uses repetitive transcranial magnetic stimulation to treat major depressive disorder. The company's stock performance and analyst sentiment can signal broader trends in the mental health treatment market and investor confidence in emerging medical technologies.

The details

Neuronetics' share price fell to $1.39, down from a previous close of $1.43. Trading volume declined 22% from the stock's average daily volume. The drop came after Canaccord Genuity Group lowered its price target on Neuronetics and Wall Street Zen downgraded the stock to a 'sell' rating.

  • Neuronetics' stock price was down 2.8% during mid-day trading on Wednesday, April 16, 2026.
  • On March 19, 2026, Neuronetics director Keith J. Sullivan sold 46,289 shares of the company's stock.

The players

Neuronetics, Inc.

A commercial-stage medical technology company that develops and markets non-invasive neuromodulation therapies for psychiatric and neurological disorders.

Canaccord Genuity Group

An investment bank that covers Neuronetics and recently lowered its price target on the stock.

Wall Street Zen

An equity research firm that downgraded Neuronetics' stock to a 'sell' rating.

Keith J. Sullivan

A director at Neuronetics who sold 46,289 shares of the company's stock on March 19, 2026.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee

The takeaway

Neuronetics' stock decline and analyst downgrades highlight the challenges facing emerging medical technology companies as they seek to gain traction and investor confidence in competitive and evolving healthcare markets.